A Comprehensive Supply Chain for Core Intermediates in Diabetes Treatment
End-to-end supply chain for anti-diabetic intermediates. Covering DPP-4, SGLT-2 inhibitors & GPR40 agonists. Stable, compliant, scalable.
March 6, 2026
Dapagliflozin Tetraacetate
(2R,3R,4R,5S,6S)-2-(Acetoxymethyl)-6-[4-chloro-3-(4-ethoxybenzyl)phenyl]tetrahydropyran-3,4,5-triyl Triacetate；Dapagliflozin Intermediates
CAS:461432-25-7
Chemical Formula:C29H33ClO10
Molecular Weight:577.02
Availability: R&D; Commercialization
Dapagliflozin Tetraacetate
⬤ CAS No.461432-25-7
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | Dapagliflozin Tetraacetate |
| CAS No. | 461432-25-7 |
| Chemical Formula | C29H33ClO10 |
| Molecular Weight | 577.02 |
| EINECS | 930-010-9 |
| Related Categories | Dapagliflozin Intermediates |
| Boiling Point | 626.8±55.0 °C(Predicted) |
| Density | 1.29±0.1 g/cm3(Predicted) |
| Vapor pressure | 0Pa at 25℃ |
| Storage conditions | Sealed in dry,Room Temperature |
| Solubility | Chloroform (dissolved in small amount), dichloromethane (dissolved in small amount), DMSO (small amount, sonicated) |
| Form | Powder |
| Stability | Stable under recommended storage conditions. |
| Note | It is used as a chemical intermediate for organic synthesis and experimental research. It is often used as an organic chemical raw material and can be used to make spices. It is also an intermediate for synthesizing various drugs in the pharmaceutical industry. |
| Core drug synthesis | Key intermediates for Dapagliflozin API |
| Key role in the synthesis process | Glycoside core structure construction |
| R&D and extended applications | Development of a new generation of SGLT2 inhibitors |
Customer Reviews
Real customer feedback
Michael Carter
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Dr. Sofia Alvarez
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Rajesh Kapoor
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Emily Zhang
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
What's News
Latest news at Tianming
CDMO vs. Direct Manufacturer: Which Model Fits Your API Strategy?
Drawing from on-the-ground experience in China’s top pharma clusters, this guide cuts through the jargon to reveal when to partner for complex innovation and when to buy from the workhorses of mature production.
March 3, 2026
Case Study: Improving Yield & Purity Through Route Optimization
This case study, based on publicly available academic literature and patents, focuses on the application of synthetic route optimization in improving the yield and purity of Active Pharmaceutical Ingredients (APIs).
February 27, 2026
Still Have Questions？
If you still have questions or need more information, our team is here to help. Please don’t hesitate to contact us for personalized assistance.